Tarceva
information and resources from the National Cancer Institute
Tarceva
(Other name for: erlotinib)Targocid
(Other name for: teicoplanin)Tarceva
(Other name for: erlotinib)
|
|
|
|
news articles
Miracle cures: The pill cabinet of the future 01 Apr 2006
Independent, The new drug for lung cancer, Tarceva, is being hailed as a breakthrough in the treatment of the disease but it costs £75 a day and must be taken for life. ...
Britain: Breast cancer patient’s legal challenge highlights ... Mar 30, 2006
Asian Tribune, Other cancer-fighting drugs such as Avastin, Erbitux, Gleevec, Rituxan and Tarceva are also increasingly deemed too expensive and are not currently widely ...
OSI Pharmaceuticals Announces Year End 2005 Financial Results Mar 7, 2006
Genetic Engineering News, ...oncology, eye diseases, and diabetes. Total world-wide net sales of Tarceva(R) (erlotinib) for 2005 were $309 million. Total US sales of ...
Targeted Agents Added to Guidelines for Non-Small Cell Lung Cancer ... Mar 20, 2006
DG News Maryland, United States. "But the most important change involved adding bevacizumab (Avastin) and erlotinib (Tarceva).". Although use ...
Genentech Boosts Earnings Forecast; Shares Rise Mar 18, 2006
Los Angeles Times, ...and after surgery. Genentech said it was looking at its new lung cancer drug Tarceva in pancreatic and breast cancers. The non-Hodgkin's ...
American Journal of Respiratory and Critical Care Medicine Vol 173 ... Mar 28, 2006
AJRCCM (subscription), ...based on phase II data. Erlotinib (Tarceva) was the second EGFR TKI to undergo evaluation. The National Cancer Institute Canada ...
OSI Pharma's Cancer Drug Data May Boost Stock Mar 13, 2006
Forbes ..."We believe the event clarified OSI's strategy on Macugen, and underscored the value in its pipeline, including new indications for Tarceva and OSI's diabetes ...
GenVec expands pancreatic cancer study Mar 16, 2006
Pharmaceutical Business Review ...therapy for five weeks, with or without a weekly intratumoral injection of TNFerade, followed by maintenance therapy (gemcitabine with or without Tarceva). ...
Oregon hits a big score with Genentech Mar 18, 2006
OregonLive.com, Program. Others will squawk about the high costs of the company's products, such as Avastin, Tarceva, Rituxin and Nutropin. But ...
OSI Pharmaceuticals Announces Year End 2005 Financial Results Mar 7, 2006
Finanzen.net, Total world-wide net sales of Tarceva(R)(erlotinib) for 2005 were $309 million. ... US marketing collaborator for Tarceva. US sales for. ...
Drugs added to cancer guidelines Mar 9, 2006
Monsters and Critics.com, ...at Johns Hopkins University School of Medicine in Baltimore, Md., 'but the most important change involved adding bevacizumab (Avastin) and erlotinib (Tarceva ...
$80M loss for OSI in fourth quarter Mar 8, 2006
Newsday, But an increase in sales of Tarceva - OSI's lung and pancreatic cancer drug - helped boost revenue in the fourth quarter, the company said yesterday. ...
Dana Reeve, a Nonsmoker, Dies of Lung Cancer at 44 Mar 7, 2006
MedPage Today, Patients with mutations in the EGF receptor may respond to two targeted therapies, Tarceva (erlotinib) and Iressa (gefitinib), a finding that was reported by Dr ...
UPDATE 1-OSI quarterly loss widens on acquisition costs Mar 7, 2006
Reuters Tuesday its quarterly loss widened due to costs related to its acquisition of Eyetech Pharmaceuticals, but revenue jumped on higher sales of Tarceva for lung ...
OSI Pharmaceuticals Files Resale Registration Statement for ... Mar 24, 2006
Genetic Engineering News, OSI's flagship product, Tarceva(R) (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have ...
Adopt Knowledge from This Analysis to Drive Strategic Planning ... Mar 25, 2006
New Age Media Concepts (press release) Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs. ...
A cancer drug's big price rise disturbs doctors and patients Mar 12, 2006
International Herald Tribune, ...drugs. Last year, Genentech raised the price of Tarceva, a lung-cancer drug, by about 30 percent, to $32,000 for a year's treatment. ...
ImClone’s Erbitux Receives FDA Label In Head And Neck Cancer Mar 2, 2006
BioWorld Online (subscription), Down the line, Genentech’s Tarceva (erlotinib), which sold $274.9 million last year, could also compete in colorectal cancer. ...
Genentech raises EPS forecast, approvals target Mar 17, 2006
MSN Money ...nutrients need to grow. Genentech said it was looking at its new lung cancer drug Tarceva in pancreatic and breast cancers. It will also ...
��：生命�纬 Mar 19, 2006
BioX, OSI Pharmaceuticals Inc. (OSIP.O: Quote, Profile, Research), whose growth engine is the cancer drug Tarceva, generated a firestorm of opposition from ...
Thalomid® and IL-2 Effective for Metastatic Renal Cell Carcinoma Mar 20, 2006
Cancer Consultants (press release), More recently other biologic agents such as SU11248, Tarceva® and Avastin® have been reported to have significant activity in the treatment of MRCC. ...
Why nonsmokers are at risk Mar 8, 2006
Newsday, Nonsmokers most often have non-small cell cancer, like Reeve, and this is more responsive to the current therapy, Tarceva, which blocks a cell growth receptor ...
Velcade Lung Cancer Study Begins Mar 6, 2006
TheStreet.com ...by the Food and Drug Administration to treat the blood cancer multiple myeloma, is also being studied to treat other lung cancers combined with Tarceva, a drug ...
Eye On Stocks For Friday, March 10 Mar 9, 2006
Forbes The biotech firm is expected to provide updates on clinical trials for Tarceva, a cancer drug co-marketed by Genentech (nyse: DNA - news - people ) and Roche ...
Experts: Nonsmoker's death from lung cancer isn't unusual Mar 7, 2006
The State, The trade names of the drugs are Tarceva, Iressa and Xyotax. Iressa is prescribed only to a limited group of patients who have already responded well to it. ...
Inflation Fears Linger Mar 3, 2006
Trading Markets, On January 11th, 2006, OSI Pharmaceuticals said its fourth quarter net US sales rose to $83.9 million and net sales of its flagship product, Tarceva, rose 15%. ...
Dana Reeve's Death Draws Attention to Lung Cancer Mar 15, 2006
International News Service, New chemotherapy agents and targeted drugs like Iressa and Tarceva have improved survival rates over the past decade, Patel said, but researchers still have a ...
GenVec Expands TNFerade Phase II Pancreatic Cancer Study into ... Mar 15, 2006
Genetic Engineering News, ...for five weeks, with or without a weekly intratumoral injection of TNFerade, followed by maintenance therapy (gemcitabine with or without Tarceva(R)). The ...
Millennium Pharmaceuticals: more Velcade ventures Mar 7, 2006
Pharmaceutical Business Review This includes a phase II NSCLC trial with Velcade plus erlotinib (marketed as Tarceva by OSI Pharmaceuticals, Genentech and Roche) as first-line therapy for ...
Gemzar Narrow Progression-Free Survival Benefit To Test Oncology ... Mar 10, 2006
FDA Advisory Committee ...number of slim efficacy advantages before the oncology committee in recent months; in committee briefing documents on Genentech/OSI’s Tarceva for pancreatic ...
Eli Lilly: Gemzar set for FDA rebuff Mar 14, 2006
Pharmaceutical Business Review ...presented with drugs that confer only a minimal survival benefit in the past, including OSI Pharmaceuticals, Genentech and Roche's Tarceva (erlotinib), which ...
Genta Incorporated Announces Fourth Quarter and Year End 2005 ... Mar 10, 2006
PR Newswire (press release), Genasense has demonstrated preclinical synergy with various treatments, such as Tarceva(R) (erlotinib), interferon and radiation, that require multi-day ...
Prescription drug purchases by Canadian hospitals and pharmacies ... Mar 15, 2006
Canada NewsWire (press release), 4 Lyrica Neurological Pfizer 3,087 June Disorders ----- 5 Tarceva Oncology Roche 1,728 July ...
S&P Ups Marsh & Mclennan and Luby's, Cuts Astrazeneca 21 Dec 2005
BusinessWeek We are positive on prospects for OSI's Tarceva drug, but concerned over the competitive landscape for Macugen, assuming Genentech's (DNA ) Lucentis drug gets ...
Reasonable premium 21 Dec 2005
Reuters ...constitute 23.8% of US sales in the third quarter) and Herceptin (up 70% to15.8% of US revenue), along with the introduction late last year of Tarceva, and its ...
New Products and Line Extensions are the Contributing Factors to ... Dec 20, 2005
Genetic Engineering News, Continued uptake of Tarceva and potential approvals for Avastin, Zactima, Erbitux and other new therapies will offset the decline in value that has come as a ...
OSI and Dana Head List of 2005's Biggest Losers Dec 19, 2005
Bloomberg It makes Tarceva, a lung- cancer drug that last month won the US Food and Drug Administration's approval for use to treat pancreatic cancer. ...
OSI Pharmaceuticals, Inc. Prices $100 Million 2.00% Convertible ... Dec 15, 2005
Genetic Engineering News, OSI intends to use the remaining net proceeds of approximately $72.0 million for the ongoing development and commercialization of Tarceva(R) and Macugen(R ...
$100 million project to get to the root of cancer Dec 14, 2005
Seattle Post Intelligencer A handful of so-called targeted drugs -- Herceptin, Gleevec, Iressa, Tarceva -- are proving remarkably effective at battling certain cancers in patients with ...
Congressman Shaw to undergo 2nd surgery for lung cancer Dec 16, 2005
Sun-Sentinel.com, He decided to take the drug Tarceva instead of immediate surgery. Tarceva "reduced the size of the tumor, kept it stable and isolated ...
OSI Pharmaceuticals, Inc. Prices $100 Million 2.00% Convertible ... Dec 15, 2005
Finanzen.net, OSI intendsto use the remaining net proceeds of approximately $72.0 million forthe ongoing development and commercialization of Tarceva(R) andMacugen(R ...
Rep. Clay Shaw set to undergo second surgery Dec 16, 2005
Fort Lauderdale Sun Sentinel, The new tumor is in the lower lobe of the same lung and Shaw decided to take the drug Tarceva instead of having immediate surgery. ...
Rush University Medical Center Studies New Agent To Treat Lung ... Dec 15, 2005
PharmaLive.com (press release), ...patients with advanced BAC who have progressed after treatment with up to two previous rounds of chemotherapy, one of which must be Iressa(R) or Tarceva(TM)(1 ...
Abelson-Taylor Wins International Award Competitions Dec 19, 2005
PharmaLive.com (press release), ...in mixed media, sales aids, and sales force education— for Evoclin, and two, including a journal ad and a CD-ROM, for its work on Tarceva (erlotinib), a drug ...
New therapy for pancreas cancer approved Dec 10, 2005
Daily News Journal (subscription), The FDA approved the addition of the targeted agent erlotinib (marketed as Tarceva) to the chemotherapy drug gemcitabine, which has been the only approved ...
Rep. Clay Shaw to have surgery for lung cancer Dec 16, 2005
Miami Herald, ...in May. Since then, Shaw has taken Tarceva, a drug that has reduced the tumor and kept it stable, but did not eliminate it. Shaw ...
Fighting Back Against Cancer Dec 13, 2005
News Letter, She has been put on a new drug tarceva and what is known as an Expanded Access Programme. Tarceva is an inhibitor drug, developed ...
OSI Announces Proposal to Offer $100 Million of Convertible Senior ... Dec 14, 2005
Business Wire (press release), OSI's flagship product, Tarceva(R) (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have ...
Fit, older lung cancer patients respond to chemotherapy Dec 18, 2005
St. Petersburg Times, New targeted therapeutic agents such as Iressa and Tarceva (and other similar targeted agents) which could be very effective in selected patients, while being ...
Toward The Future Of Cancer Prevention Dec 18, 2005
Science Daily (press release) ...in collaboration with Nordic investigators to prevent oral cancer with two molecular-targeted drugs (Celebrex and erlotinib, also known as Tarceva®) in people ...
US speeding up cancer research Dec 14, 2005
Gainesville Sun, A handful of drugs - Herceptin, Gleevec, Iressa, Tarceva - are proving remarkably effective at battling cancers in patients with specific faulty genes. ...
US launches cancer gene mapping project Dec 13, 2005
Malaysia Star, ...p53 gene involved in many different tumors, and the EGFR gene targeted by AstraZeneca Plc's Iressa and Genentech and OSI Pharmaceutical's Tarceva, which have ...
EU experts back Astra cancer drug "orphan" status Dec 14, 2005
Reuters The once-daily pill combines the action of Iressa and Tarceva -- a rival product made by Genentech Inc (DNA.N: Quote, Profile, Research) and Roche Holding AG ...
Experts to Create Genetic Map of Cancer Dec 13, 2005
Leading The Charge, ...patients have the genetic aberration that Herceptin targets, and just 10 percent of lung cancer sufferers harbor the mutation that Iressa and Tarceva target. ...
OSI Announces Proposal to Offer $100 Million of Convertible Senior ... Dec 14, 2005
Finanzen.net, OSI'sflagship product, Tarceva(R) (erlotinib), is the first drug discoveredand developed by OSI to obtain FDA approval and the only EGFRinhibitor to have ...
Abelson-Taylor Promotes Four to Account Director Dec 5, 2005
PharmaLive.com (press release), ...management team for Genentech’s Rituxan (rituximab) in the US , she will also continue to direct account activities for Roche’s Tarceva (erlotinib) in ...
Roche "buy" Dec 6, 2005
New Ratings ...note published this morning, the analysts mention that the company has benefited in the recent past from the clinical success of Avastin, Herceptin and Tarceva ...
Researchers probe links between gender and cancer Dec 8, 2005
Pittsburgh Post Gazette, ...were promising and Pittsburgh, along with the University of California, Los Angeles, is now enrolling 120 men and women to test Tarceva, another targeted ...
Scrip Awards Dec 9, 2005
PR Newswire (press release), Roche's novel cancer therapies, Avastin and Tarceva, jointly won the Best New Drug award for their role in treating this devastating disease. ...
Trying not to miss a beat Dec 10, 2005
Austin American-Statesman (subscription), While Bocian has declined radiation and chemotherapy, he has started taking another drug called Tarceva, usually given to patients with advanced lung cancer ...
Heading Off Heart Attacks Dec 12, 2005
TechnologyReview.com Earlier this year, for example, scientists discovered a key SNP that makes the cancer drugs Iressa and Tarceva much more effective in people who carry the ...
Lung cancer in women Dec 11, 2005
ITP.net, Targeted agents like Iressa and Tarceva, for example, may be used more often or earlier in women, especially nonsmokers, because they seem to respond better ...
Licensing is pivotal to Pharmaceutical Industry evolving ... Dec 8, 2005
PharmaLive.com (press release), About 50% of Wood Mackenzie's forecast $29.7bn revenues will be from in-licensed products, driven by strong growth of Herceptin, Tarceva, MabThera and Avastin ...
New Product Launches in the Cancer Market such as Erbitux, Avastin ... Nov 21, 2005
Business Wire (press release), DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 21, 2005--Research and Markets (http://www.researchandmarkets.com/reports/c28122) has announced ...
New Product Launches in the Cancer Market such as Erbitux, Avastin ... Nov 21, 2005
PharmaLive.com (press release), DUBLIN, Ireland--(BUSINESS WIRE)--Nov 21, 2005 - Research and Markets (http://www.researchandmarkets.com/reports/c28122) has announced the addition of The ...
AEterna Zentaris appoints a Board Vice Chairman, a New Chair of ... Nov 21, 2005
Yahoo! News (press release) ...he was involved in the early development of many of the agents now used routinely, including: Paclitaxel, Docetaxel, Gemcitabine, CPT-11, Iressa and Tarceva. ...
The Market for Existing Targeted Therapies Worth $5.1 Billion in ... Nov 23, 2005
Genetic Engineering News, ...and Novartis' Glivec to maintain their blockbuster status, while allowing newer products such as Genentech/Roche's Herceptin, Avastin and Tarceva to break the ...
Monoclonal Antibody Combination Effective in Advanced Renal Cell ... Nov 29, 2005
Cancerpage.com, ...with metastatic clear-cell renal carcinoma who were given bevacizumab (Avastin ) 10 mg/kg intravenously every two weeks and 150 mg of erlotinib (Tarceva) daily ...
Running at cancer head-on Nov 17, 2005
TimesCommunity.com, This fall, the Food and Drug Administration approved a drug, Tarceva, that has been shown to extend the lives of some sufferers. ...
Cancer survivor Nov 29, 2005
Grenada Daily Star, Her follow-up reports have been good, Young said. "At this time, I am on Tarceva and am doing great...stable scans each time I have gone to the clinic.". ...
To Walk Again Nov 23, 2005
Forbes Genentech is now testing in mice whether its lung cancer drug Tarceva can spur nerve regrowth, following positive preliminary findings published last month by ...
Pharma Reformulates Dec 5, 2005
Chemical & Engineering News Schering-Plough's combination cholesterol-lowering product Vytorin; OSI Pharmaceuticals, Genentech, and Roche's lung cancer drug Tarceva; Boehringer Ingelheim ...
Biotech Field Shows New Life Nov 18, 2005
Investor's Business Daily (subscription) ...the fruits of these techniques. Its drugs include Avastin, Tarceva and Herceptin. Pharmacogenics is another important technology ...
|
|
